SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a major policy catalyst following an executive order signed by President Trump, which aims to accelerate FDA breakthrough therapy reviews for psychedelic-based treatments like psilocybin and MDMA. The community is actively discussing the stock's potential re-rating and its position in the broader mental health innovation sector, with many focused on upcoming Phase 3 trial data as a primary catalyst for future valuation growth.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is drawing attention as investors highlight its fundamental strength and consistent revenue generation compared to other DeFi protocols. The community remains focused on long-term accumulation, closely monitoring technical support levels and broader market volatility as traders debate the project's potential for future growth.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is driving intense community engagement through its multichain presence and deflationary burn mechanism, with supporters actively building a cult-like following. Investors are heavily focused on the project's long-term potential, frequently encouraging others to increase their positions while highlighting the meme's unique brand identity.

Highstreet

Highstreet is seeing intense community debate and speculative trading as users analyze its potential for a short squeeze following a significant pullback from previous highs. Discussions are heavily polarized, with many traders debating the risk of further declines against the potential for a rapid technical reversal based on low supply and oversold indicators.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is experiencing significant volatility and heightened investor interest as the market reacts to a major rebrand and leadership changes, while simultaneously tracking key clinical catalysts including Phase 2 readouts for its anxiety pipeline and Phase 3 progress for its lead depression program. Community discussions are deeply polarized, with some investors focusing on the company's strong patent portfolio and potential for a sector-wide regulatory re-rating, while others remain skeptical due to historical dilution, poor stock performance, and the company's rebranding efforts.

PolySwarm

PolySwarm is capturing investor attention as the community anticipates a long-awaited breakout, driven by its cybersecurity utility and low market cap. Discussion is currently dominated by bullish sentiment regarding the token's potential for explosive gains, whale accumulation patterns, and hopes for upcoming catalysts that could trigger a significant price reversal.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing a wave of bullish momentum fueled by speculative reports of Middle East diplomatic progress, triggering a significant short squeeze that has captured the attention of traders. The community remains deeply divided, with bulls aggressively targeting the $80,000 level and calling for a structural breakout, while vocal bears argue the asset is caught in a classic bear trap and remains structurally weak.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following a major executive order that prioritizes the fast-tracking of psychedelic therapies for mental health, fueling community anticipation for potential upcoming clinical trial readouts and regulatory shifts. Investors are actively discussing the stock's position as an industry leader and its pivotal role in the developing psychedelics sector amid broader policy tailwinds.

The Internet Computer is a decentralized cloud blockchain designed to run applications, websites, and backend systems fully on-chain. Its architecture provides robust security, resilience, and built-in multi-chain support.  A key focus of the network is enabling a “self-writing cloud,” where AI tools allow users generate applications through natural-language instructions.  Developers and users can experiment with the platform using AI app-generation tools like caffeine.ai or by writing serverless code directly through online IDEs such as icp.ninja.  The ICP token is used to pay for computation (through a burn-based model) and to participate in network governance through staking.

Internet Computer

Internet Computer (ICP) is attracting significant community attention as users debate its long-term potential as a decentralized cloud infrastructure alternative to Big Tech. While some investors remain skeptical due to past price performance and dilution concerns, proponents are actively promoting its technical milestones like the Caffeine.ai integration and the launch of sovereign subnets as catalysts for future mainstream adoption.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to anticipation surrounding the upcoming CHOPIN trial data, expected in mid-October, which investors hope will validate the platform's clinical value and potentially expand the Hepzato Kit's use as a frontline treatment. While recent revenue guidance and management's explanation of seasonal slowdowns caused significant volatility, the community remains divided, with bulls pointing to growing center activations, strong gross margins, and long-term pipeline potential in additional cancer indications as reasons to accumulate at lower price levels.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sprinklr, Inc. (NYSE:CXM) Given Average Recommendation of "Reduce" by Brokerages

Sprinklr, Inc. (NYSE:CXM - Get Free Report) has received a consensus recommendation of "Reduce" from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and two...

Sprinklr, Inc. (NYSE:CXM) Short Interest Update

Sprinklr, Inc. (NYSE:CXM - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 30,396,270 shares, a...

Tudor Investment Corp ET AL Trims Stake in Sprinklr, Inc. $CXM

Tudor Investment Corp ET AL lowered its holdings in Sprinklr, Inc. (NYSE:CXM - Free Report) by 34.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange...

Sprinklr Unveils Next Wave of AINative Customer Experience Innovation with Spring 26 (26.4) Release

Sprinklr (NYSE: CXM), the AInative Unified Customer Experience Management (UnifiedCXM) platform, today announced the Spring 26 Release (26.4) a major advancement in AIpowered insights, marketing...

Sprinklr and CreatorIQ Announce Strategic Partnership to Unify Creator, Organic, and Paid Social Media

Sprinklr (NYSE: CXM), the definitive, AI-native platform for Unified Customer Experience Management (Unified-CXM), and CreatorIQ, the global operating system for creator-led growth, today announced a...

SG Americas Securities LLC Has $35.25 Million Stock Position in Sprinklr, Inc. $CXM

SG Americas Securities LLC lifted its stake in shares of Sprinklr, Inc. (NYSE:CXM - Free Report) by 11,204.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The...

Tudor Investment Corp ET AL Sells 598,892 Shares of Sprinklr, Inc. $CXM

Tudor Investment Corp ET AL lessened its stake in Sprinklr, Inc. (NYSE:CXM - Free Report) by 34.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,157,977 shares of the company's stock after selling 598,892 s...

Sprinklr, Inc. (NYSE:CXM) Given Average Rating of "Hold" by Brokerages

Sprinklr, Inc. (NYSE:CXM - Get Free Report) has earned a consensus rating of "Hold" from the nine analysts that are covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and two have given a buy recommendation...

Insider Selling: Sprinklr (NYSE:CXM) CTO Sells 34,189 Shares of Stock

Sprinklr, Inc. (NYSE:CXM - Get Free Report) CTO Amitabh Misra sold 34,189 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of...

Fulcrum Asset Management LLP Lowers Stock Position in Sprinklr, Inc. $CXM

Fulcrum Asset Management LLP cut its stake in shares of Sprinklr, Inc. (NYSE:CXM - Free Report) by 85.8% in the third quarter, according to the company in its most recent filing with the Securities...

Sprinklr, Inc. engages in the provision of enterprise cloud software products. It enables organizations to do marketing, advertising, research, care, sales, and engagement across modern channels including social, messaging, chat, and text through its unified customer experience management software platform. The company was founded by Ragy Thomas on September 24, 2009 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.10	--	--	N/A
Q4 '25	$0.10	$0.13	35.17%	BEAT
Q3 '25	$0.09	$0.12	31.26%	BEAT
Q2 '25	$0.10	$0.13	29.67%	BEAT
Q1 '25	$0.10	$0.12	21.86%	BEAT

CXM
Sprinklr Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CXM News

CXMSprinklr Inc